Sign In
Buy CTXR
$0.570
-0.0620 (-9.81%)
At Close: Jul 31, 2026
Study, in patients with solid tumors focusing on gynecological malignant tumors such as ovarian, endometrial, and cervical, nearing completion with three remaining subjects to be enrolled 27% Objectiv
Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
04:30pm, Thursday, 05'th Sep 2024
CEO Leonard Mazur to present on Tuesday, September 10, 2024, at 9:00 am ET CRANFORD, N.J. , Sept. 5, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR)
CRANFORD, N.J. , Sept. 5, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), today announ
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update
05:28pm, Monday, 12'th Aug 2024
Granted FDA approval of LYMPHIR™ for the treatment of cutaneous T-cell lymphoma Completed merger of oncology subsidiary with TenX Keane; Citius Oncology expected to begin trading on Nasdaq on August
Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc.
04:22pm, Monday, 12'th Aug 2024
LYMPHIR™ for the treatment of cutaneous T-cell lymphoma approved by the FDA Citius Pharmaceuticals, Inc. holds approximately 90% of publicly traded Citius Oncology, Inc. Shares of Citius Oncology, I
Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments
08:00am, Monday, 12'th Aug 2024
Management call scheduled for Tuesday, August 13, 2024, at 8:30 AM ET CRANFORD, N.J. , Aug. 12, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), tod
Only systemic treatment for relapsed or refractory (r/r) CTCL to target the IL-2 receptor on malignant T-cells and Tregs LYMPHIR is expected to launch within the next five months LYMPHIR's approval ma
Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc.
08:00am, Monday, 05'th Aug 2024
Citius Pharmaceuticals to receive 65.6 million shares of TenX Keane, which will be renamed Citius Oncology, Inc. Citius Pharmaceuticals to retain approximately 90% majority control post transaction
Biotech Stocks Race Towards Solutions for Cutaneous T-Cell Lymphoma (CTCL)
07:00am, Thursday, 18'th Jul 2024
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - July 18, 2024) - Investorideas.com, a go-to investing platform releases the second of a two-part series looking at biotech/biopharma
Analysts Hunt for Undervalued Biotech Stocks
08:00am, Wednesday, 17'th Jul 2024
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - July 17, 2024) - Investorideas.com, a go-to investing platform releases the first of a two-part series looking at biotech/biopharma s
Bloodstream Infections - From Threats to Solutions
11:00am, Thursday, 11'th Jul 2024
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - July 11, 2024) - Investorideas.com, a go-to investing platform releases the second of a two-part series looking at recent news and de
Biopharma Stocks Transformative Innovation for the Future of Health
08:00am, Thursday, 11'th Jul 2024
Vancouver, Kelowna and Delta, British Columbia--(Newsfile Corp. - July 11, 2024) - Investorideas.com, a go-to investing platform releases the first of a two-part series looking at transformative innov
Citius Pharmaceuticals Details Near-Term Milestones for Late-Stage Candidates
09:10am, Wednesday, 10'th Jul 2024
Multiple catalysts for potentially transformative assets in second half of 2024 Strong momentum expected from positive topline results of Phase 3 Mino-Lok® trial, commercialization of LYMPHIR™ if a
Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution
08:30am, Wednesday, 29'th May 2024
Management call scheduled for Monday, June 3, 2024 at 8:30 AM ET CRANFORD, N.J. , May 29, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage bio
Why Is Citius Pharmaceuticals (CTXR) Stock Up 11% Today?
10:58am, Tuesday, 21'st May 2024
Citius Pharmaceuticals (NASDAQ: CTXR ) stock is on the rise Tuesday after the company announced new results from its Phase 3 clinical trial of Mino-Lok. Mino-Lok is Citius Pharmaceuticals' antibiotic
